A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual agonism of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor may be more effective than GLP-1 receptor agonism alone for treating metabolic dysfunction-associated steatohepatitis (MASH). The efficacy and safety of survodutide (a dual agonist of glucagon receptor and GLP-1 receptor) in persons with MASH and liver fibrosis are unclear. METHODS: In this 48-week, phase 2 trial, we randomly assigned adults with biopsy-confirmed MASH and fibrosis stage F1 through F3 in a 1:1:1:1 ratio to receive once-weekly subcutaneous injections of survodutide at a dose of 2.4, 4.8, or 6.0 mg or placebo. The trial had two phases: a 24-week rapid-dose-escalation phase, followed by a 24-week maintenance phase. The primary end point was histologic improvement (reduction) in MASH with no worsening of fibrosis. Secondary end points included a decrease in liver fat content by at least 30% and biopsy-assessed improvement (reduction) in fibrosis by at least one stage. RESULTS: A total of 293 randomly assigned participants received at least one dose of survodutide or placebo. Improvement in MASH with no worsening of fibrosis occurred in 47% of the participants in the survodutide 2.4-mg group, 62% of those in the 4.8-mg group, and 43% of those in the 6.0-mg group, as compared with 14% of those in the placebo group (P<0.001 for the quadratic dose-response curve as best-fitting model). A decrease in liver fat content by at least 30% occurred in 63% of the participants in the survodutide 2.4-mg group, 67% of those in the 4.8-mg group, 57% of those in the 6.0-mg group, and 14% of those in the placebo group; improvement in fibrosis by at least one stage occurred in 34%, 36%, 34%, and 22%, respectively. Adverse events that were more frequent with survodutide than with placebo included nausea (66% vs. 23%), diarrhea (49% vs. 23%), and vomiting (41% vs. 4%); serious adverse events occurred in 8% with survodutide and 7% with placebo. CONCLUSIONS: Survodutide was superior to placebo with respect to improvement in MASH without worsening of fibrosis, warranting further investigation in phase 3 trials. (Funded by Boehringer Ingelheim; 1404-0043 ClinicalTrials.gov number, NCT04771273; EudraCT number, 2020-002723-11.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationA phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citationChanging epidemiology, global trends and implications for outcomes of NAFLD
Wong, V. W.-S., Ekstedt, M., Wong, G. L.-H., & Hagström, H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.036 · Cited by 765
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Loomba, R., Sanyal, A. J., Kowdley, K. V., Bhatt, D. L., Alkhouri, N., Frias, J. P., Bedossa, P., Harrison, S. A., Lazas, D., Barish, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304286 · Cited by 522
Self-citationGlucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323
Cited by
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Self-citationType 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Lu, X., Xie, Q., Pan, X., Zhang, R., Zhang, X., Peng, G., Zhang, Y., Shen, S., & Tong, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01951-9 · Cited by 665
“278 The effects of GLP-1 on ameliorating hepatic in fl ammation, steatosis, and injury are thought to be secondary to weight loss and improved hepatocyte lipid synthesis and oxidation.”
BackgroundEuropean Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 471
Stefan, N., Yki-Järvinen, H., & Neuschwander-Tetri, B. A. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00318-8 · Cited by 392
Cusi, K., Abdelmalek, M. F., Apovian, C. M., Balapattabi, K., Bannuru, R. R., Barb, D., Bardsley, J. K., Beverly, E. A., Corbin, K. D., ElSayed, N. A., et al. (2025) · Diabetes Care · doi:10.2337/dci24-0094 · Cited by 332
Self-citationIsraelsen, M., Francque, S., Tsochatzis, E. A., & Krag, A. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01811-7 · Cited by 348
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
“…of GLP-1 and glucagon receptor, in 293 people with biopsy-proven MASH and stage 1–3 fibrosis determined that improvement in MASH without worsening fibrosis was higher in those who received 2.4 mg, 4.8 mg and 6.0 mg, compared with placebo (47%, 62%, 43% and 14%, respectively, P 0.001) 273 .”
InfluentialMetabolic Dysfunction–Associated Steatotic Liver Disease
Targher, G., Valenti, L., & Byrne, C. D. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2412865 · Cited by 325
Natural history and progression of metabolic dysfunction-associated steatotic liver disease
Hagström, H., Shang, Y., Hegmar, H., & Nasr, P. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00193-6 · Cited by 310
Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults: A Review
Tilg, H., Petta, S., Stefan, N., & Targher, G. (2026) · JAMA · doi:10.1001/jama.2025.19615 · Cited by 221
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
“Gastrointestinal adverse events were much more common in survodutide-treated patients 125 .”
InfluentialAlfaris, N., Waldrop, S., Johnson, V., Boaventura, B., Kendrick, K., & Stanford, F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102782 · Cited by 224
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Cusi, K., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s004 · Cited by 205
Zheng, H., Sechi, L. A., Navarese, E. P., Casu, G., & Vidili, G. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02434-5 · Cited by 185
“These findings underscore the promise of survodutide as a therapeutic candidate, warranting its advancement into phase 3 clinical trials for the treatment of MASH and associated liver fibrosis [144].”
BackgroundRaverdy, V., Tavaglione, F., Chatelain, E., Lassailly, G., De Vincentis, A., Vespasiani-Gentilucci, U., Qadri, S. F., Caiazzo, R., Verkindt, H., Saponaro, C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03283-1 · Cited by 169
“…, or to drugs favoring weight loss and cardiovascular risk reduction, namely, the glucagon-like peptide-1 (GLP1) receptor agonist semaglutide 31 , the GLP1–glucose-dependent insulinotropic polypeptide receptor dual agonist tirzepatide 32 or the GLP1–glucagon receptor dual agonist survodutide 33 .”
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Do, A., Zahrawi, F., & Mehal, W. Z. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01084-2 · Cited by 169
“In a longer-term phase II trial, 62% of participants treated with survodutide showed biopsy-proven improvement in MASH after 48 weeks, without worsening of fibrosis, compared with 14% of controls (NCT06309992) 126 .”
Eslam, M., Fan, J.-G., Yu, M.-L., Wong, V. W.-S., Cua, I. H., Liu, C.-J., Tanwandee, T., Gani, R., Seto, W.-K., Alam, S., et al. (2025) · Hepatology International · doi:10.1007/s12072-024-10774-3 · Cited by 170
“Survodutide is another GLP-1/glucagon dual agonist that demonstrated histological improvement of MASH in a phase 2 randomized trial [245].”
Chew, N. W. S., Mehta, A., Goh, R. S. J., Zhang, A., Chen, Y., Chong, B., Chew, H. S. J., Shabbir, A., Brown, A., Dimitriadis, G. K., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.070535 · Cited by 167
“72 Although recommending GLP1-RA and SGLT2 inhibitors may be premature for the management of MASLD in normal-weight individuals, these agents may be considered to reduce cardiovascular events in individuals with T2D, ASCVD, and target organ damage 32,33 (Recommendation 4.13; Table 2).”
InfluentialSelf-citationECM formation and degradation during fibrosis, repair, and regeneration
Mayorca-Guiliani, A. E., Leeming, D. J., Henriksen, K., Mortensen, J. H., Nielsen, S. H., Anstee, Q. M., Sanyal, A. J., Karsdal, M. A., & Schuppan, D. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00063-4 · Cited by 176
Self-citationLipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
Lin, J., Huang, Y., Xu, B., Gu, X., Huang, J., Sun, J., Jia, L., He, J., Huang, C., Wei, X., et al. (2025) · BMJ · doi:10.1136/bmj-2024-083735 · Cited by 168
Stefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Loomba, R. S., Bédossa, P., Grimmer, K., Kemble, G. W., Martins, E. B., McCulloch, W. F., O’Farrell, M., Tsai, W.-W., Cobiella, J., Lawitz, E., et al. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00246-2 · Cited by 126
Self-citationde Souza, M. H. G., Al‐Sharif, L., Antunes, V., Huang, D. Q., & Loomba, R. (2025) · Hepatology · doi:10.1097/hep.0000000000001254 · Cited by 124
Obesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction
Choi, W., Woo, G. H., Kwon, T., & Jeon, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199715 · Cited by 130
“Survodutide (GLP-1/Glucagon dual) improved MASH without fibrosis worsening in phase-2, and human studies show glucagon-receptor activation increases hepatic mitochondrial oxidation and pyruvate carboxylase flux, providing direct metabolic evidence for this class [244,245].”
Min, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s506957 · Cited by 132
Byrne, C. D., Armandi, A., Pellegrinelli, V., Vidal‐Puig, A., & Bugianesi, E. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01045-z · Cited by 136
“…MASH and moderate or severe fibrosis, the dual GLP1–glucagon receptor agonist, survodutide, achieved similar results, with a highly marked decrease in liver fat content and improvement in MASH even for non-maximal doses of survodutide and was associated with a significant anti-fibrotic effect 137 .”
Self-citationLipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)
Iturbe-Rey, S., Maccali, C., Arrese, M. A., Aspichueta, P., de Oliveira, C. P. M. S., Castro, R. E., Lapitz, A., Izquierdo‐Sánchez, L., Bujanda, L., Perugorria, M. J., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.119053 · Cited by 129
Romeo, S., Vidal‐Puig, A., Husain, M., Ahima, R. S., Arca, M., Bhatt, D. L., Diehl, A. M., Fontana, L., Foo, R., Frühbeck, G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf314 · Cited by 108
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s004 · Cited by 133
Self-citationFan, J., Xu, X., Yang, R.-X., Nan, Y., Wei, L., Jia, J., Zhuang, H., Shi, J., Li, X., Cm, S., et al. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00311 · Cited by 152
“123,124 Therefore, these newly developed dual agonists demonstrate better therapeutic effects than GLP-1 receptor agonists, warranting further investigation in phase 3 trials.”
Truong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
Immunopathogenic mechanisms and immunoregulatory therapies in MASLD
He, Y., Chen, Y., Qian, S., van Der Merwe, S., Dhar, D., Brenner, D. A., & Tacke, F. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01307-5 · Cited by 81
“Survodutide, a GLP-1/glucagon dual agonist, resulted in signi fi cant weight loss and histological MASH resolution as well as fi brosis improvement after one year of treatment [189].”
Therapeutic horizons in metabolic dysfunction–associated steatohepatitis
Newsome, P. N., & Loomba, R. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186425 · Cited by 90
“Consequently, survodutide is now being studied in a phase III trials for MASH (22).”
Self-citationLin, R., Sun, Q., Xin, X., Ng, C. H., Valenti, L. V. C., Hu, Y., Zheng, M., & Feng, Q. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156043 · Cited by 73
Epidemiology of liver diseases: global disease burden and forecasted research trends
Xiao, J., Wang, F., Yuan, Y., Gao, J., Lu, X., Chao, Y., Guo, F., Zhong, J., Che, Z., Li, W., et al. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2722-2 · Cited by 74
“…candidates are currently in late-stage trials, including farnesoid X receptor agonists like obeticholic acid (Younossi et al., 2019) and GLP-1 receptor agonists such as semaglutide (Loomba et al., 2023) or co-agonists like survodutide (Sanyal et al., 2024) or tirzepatide (Loomba et al., 2024).”
Díaz, L. A., Arab, J. P., Idalsoaga, F. J., Perelli, J., Vega, J. A., Dirchwolf, M., Carreño, J., Samith, B., Valério, C. M., Moreira, R. O., et al. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101903 · Cited by 86
Younossi, Z. M., Razavi, H. A., Sherman, M., Allen, A. M., Anstee, Q. M., Cusi, K. J., Friedman, S. L., Lawitz, E., Lazarus, J. V., Schuppan, D., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70020 · Cited by 78
“Asia was particularly affected, with 48% of global liver-related complications and 46% of MASLD-related deaths [84].”
Self-citationLawitz, E., Fraessdorf, M., Neff, G. W., Schattenberg, J. M., Noureddin, M., Alkhouri, N., Schmid, B., Andrews, C. P., Takács, I., Hussain, S. A., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.003 · Cited by 66
Self-citationDiabetes as a risk factor for MASH progression
Gancheva, S., Roden, M., & Castéra, L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111846 · Cited by 65
Gries, J. J., Lazarus, J. V., Brennan, P., Siddiqui, M. S., Targher, G., Lang, C. C., Virani, S. S., Lavie, C. J., Isaacs, S. D., Arab, J. P., et al. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00310-8 · Cited by 68
Pediatric MASLD: current understanding and practical approach
Stroes, A.-S. R., Vos, M. B., Benninga, M. A., & Koot, B. G. P. (2024) · European Journal of Pediatrics · doi:10.1007/s00431-024-05848-1 · Cited by 59
“Glucagon-like-peptide-1 (GLP1) receptor agonists, combined GLP-1 and glucagon receptor dual agonists and FGF-21 agonists, showed promising results in phase 2 studies in adults [121–123].”
Panganiban, J. A., Kehar, M., Ibrahim, S. H., Hartmann, P., Sood, S., Hassan, S. M., Ramirez, C. M., Kohli, R., Censani, M., Mauney, E. E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100164 · Cited by 73
“Survodutide, a dual GLP-1 and glucagon receptor agonist improved MASH without worsening in fibrosis in a phase 2 trial in adults [150].”
Singh, A., Sohal, A., & Batta, A. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i48.5205 · Cited by 52
“In a recent phase 2 study, Sanyal et al [37] investigated the efficacy of Survodutide, a GCGR/GLP-1 RA, compared to placebo in patients with biopsy-confirmed MASH and fibrosis ranging from F1 to F3 stages.”
The growing range of complications of diabetes mellitus
Hamblin, P. S., Russell, A. W., Talic, S., & Zoungas, S. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.12.006 · Cited by 58
Targher, G., Mantovani, A., Byrne, C. D., & Tilg, H. (2025) · Gut · doi:10.1136/gutjnl-2024-334023 · Cited by 48
“…2 placebo-controlled RCTs (with a follow-up length of at least 48 weeks) that have examined the hepatoprotective effects of subcutaneous semaglutide, 41 survodutide 47 or tirze-patide 50 on resolution/improvement of MASH and ≥1 stage fibrosis improvement in patients with MASH and liver fibrosis.”
Wang, Y., Zhou, Y., Wang, Z., Ni, Y., Prud’homme, G. J., & WANG, Q. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf336 · Cited by 64
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 70
Sattar, N. A., & Lee, M. M. Y. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00363-2 · Cited by 58
Zafer, M., Tavaglione, F., Romero‐Gómez, M., & Loomba, R. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70196 · Cited by 47
Noureddin, M., Harrison, S. A., Loomba, R. S., Alkhouri, N., Chalasani, N., Sheikh, M. Y., Tomah, S., Gutierrez, J. A., Urbina, S., Suschak, J. J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02114-2 · Cited by 66
Self-citationArmandi, A., Rosso, C., Caviglia, G. P., & Bugianesi, E. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156080 · Cited by 53
Self-citationEmerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 54
“Studies in 293 subjects with biopsy-confirmed MASH showed improved MASH without worsening fibrosis in 47%, 62%, and 43% of participants receiving 2.4 mg, 4.8 mg, and 6.0 mg doses, respectively, versus 14% with placebo [103,108].”
InfluentialMadsbad, S., & Holst, J. J. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472408 · Cited by 43
“In a 48 weeks phase 2 trial with survodutide in 393 participants with biopsy-confirmed MASH and fibrosis stage 1 through 3, improvement in MASH with no worsening of fibrosis was observed in 47% with 2.4-mg group, and 62% in in the 4.8 -mg group compared with 14% in the placebo group [110].”
InfluentialTantu, M. T., Farhana, F. Z., Haque, F., Koo, K. M., Qiao, L., Ross, A. G., & Shiddiky, M. J. A. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00030-2 · Cited by 57
Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis
Li, W., Alazawi, W., & Loomba, R. S. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00260-2 · Cited by 57
O'Keefe, J. H., Franco, W. G., & O'Keefe, E. L. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.12.010 · Cited by 42
Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders
Fiorucci, S., Urbani, G., Distrutti, E., & Biagioli, M. (2025) · Pharmaceuticals · doi:10.3390/ph18091424 · Cited by 47
Westermeier, F., & Fisman, E. Z. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02608-9 · Cited by 45
“Similarly, survodutide, another dual GLP-1R/glucagon receptor agonist (GCGR), was studied in adults with MASH and stage 1–3 fibrosis and showed superiority over placebo in improving MASH without worsening fibrosis [52].”
Pharmacological treatment of MASLD: contemporary treatment and future perspectives
Drygalski, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136518 · Cited by 39
“In the NCT04771273 trial, survodutide—another dual GLP-1/glucagon receptor agonist—was evaluated in patients with biopsy-proven MASH and fibrosis stages F1– F3 [78].”
Wharton, S., le Roux, C. W., Kosiborod, M., Platz, E., Brueckmann, M., Jastreboff, A. M., Hussain, S. A., Pedersen, S. D., Borowska, L., Unseld, A., et al. (2024) · Obesity · doi:10.1002/oby.24184 · Cited by 46
Self-citationThe steatotic liver disease burden paradox: unravelling the key role of alcohol
Torp, N., Israelsen, M. E., & Krag, A. A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01022-y · Cited by 46
“Glucagon-like peptide 1 (GLP1) receptor agonists and drugs with dual or triple agonism for the glucagon-receptor glucose-dependent insulinotropic polypeptide receptor and GLP1 receptors are other examples of drugs that attenuate hepatic inflammation and steatosis 116,117 .”
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women
Milani, I., Chinucci, M., Leonetti, F., & Capoccia, D. (2025) · Biomedicines · doi:10.3390/biomedicines13040855 · Cited by 38
“For example, the combination of GIP with GLP1-RAs has been shown to significantly improve MASH, reduce fibrosis, and decrease liver steatosis [345–347], while also having a synergistic effect on cardiometabolic risk factors [348–350].”
Nakamura, T., Masuda, A., Nakano, D., Amano, K., Sano, T., Nakano, M., & Kawaguchi, T. (2025) · Cells · doi:10.3390/cells14060428 · Cited by 47
Key takeaways from the updated multidisciplinary European MASLD guidelines
Horn, P., & Tacke, F. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100196 · Cited by 43
“36 37 No histological outcome data are currently available for the use of SGLT2i, metformin or statins in people with MASLD.”
Stefanakis, K., Mingrone, G., George, J., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156082 · Cited by 39
Kim, H. Y., & Rinella, M. E. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0083 · Cited by 37
Wong, V. W., Amin, N. B., Takahashi, H., Darekar, A., Tacke, F., Kiszko, J., Rodriguez, H., Nakajima, A., Alkhouri, N., Charlton, M., et al. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00128-1 · Cited by 39
Self-citationDavies, M. J., Lim, S. K., Slater, T., Goldney, J., Philis‐Tsimikas, A., Franco, D. R., Lamptey, R., Yates, T. E., Tankova, T. I., & Lingvay, I. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00687-w · Cited by 61
Survodutide for the Treatment of Obesity
Kosiborod, M., Platz, E., Wharton, S., le Roux, C. W., Brueckmann, M., Hussain, S. A., Unseld, A., Startseva, E., & Kaplan, L. M. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.09.004 · Cited by 42
Self-citationBahitham, W., Banoun, Y., Aljahdali, M., Almuaiqly, G., Bahshwan, S. M., Aljahdali, L., Sanai, F. M., Rosado, A. S., & Sergi, C. M. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1637071 · Cited by 41
MetALD : New Perspectives on an Old Overlooked Disease
Ayares, G., Díaz, L. A., Idalsoaga, F. J., Alkhouri, N., Noureddin, M., Bataller, R. A., Loomba, R. S., Arab, J. P., & Arrese, M. A. (2025) · Liver International · doi:10.1111/liv.70017 · Cited by 40
Self-citationZhou, X., Fan, Q.-Y., Byrne, C. D., Targher, G., Muthiah, M. D., Huang, D. Q., Chen, Q., Noureddin, M., Li, W., Ratziu, V., et al. (2025) · Gut · doi:10.1136/gutjnl-2025-337431 · Cited by 44
Self-citationNovel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart–liver co-management
Zhou, X., Lazarus, J. V., Krittanawong, C., Targher, G., Byrne, C. D., Younossi, Z. M., Tacke, F., Chen, Q., Mantzoros, C. S., Tilg, H., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00323-1 · Cited by 50
Puengel, T., & Tacke, F. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2374463 · Cited by 34
“The figure was created with BioRender.com. significant improvement of hepatic fibrosis (34–36% vs. 24% in placebo) after one year of therapy [64].”
Alkhouri, N., Charlton, M., Gray, M. E., & Noureddin, M. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2473062 · Cited by 34
“The safety and efficacy of survodutide was evaluated in a Phase II study in individuals with MASH and liver fibrosis [174].”
Self-citationMechanism-guided drug development and treatment for liver fibrosis: a clinical perspective
Zeng, X., Huang, D., Zhu, Z., Cai, Q., Yang, Y., Lu, H., & Chen, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1574385 · Cited by 36
HFpEF and MASLD: converging mechanisms and clinical implications
Capone, F., Häseli, S. P., Liu, L., Strocchi, S., Langenberg, C., Lusis, A. J., Pietzner, M., Muoio, D. M., Rider, O. J., Raman, B., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01257-z · Cited by 37
“Similarly, in a phase II trial involving patients with MASH, the dual GLP1R–glucagon receptor agonist survodutide showed benefits in histological parameters 395 .”
The expanding benefits of GLP-1 medicines
Gonzalez-Rellan, M. J., & Drucker, D. J. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102214 · Cited by 42
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease
Díaz, L. A., Thiele, M. S., Louvet, A., Lee, B. P., Ajmera, V. H., Tavaglione, F., Hsu, C. L., Huang, D. Q., Pose, E., Bataller, R. A., et al. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01120-5 · Cited by 38
“Other dual or triple agonists, including tirzepatide ( n = 190, NCT04166773) 165 , survodutide ( n = 293, NCT04771273) 166 , pemvidutide ( n = 94, NCT05006885) 167 and retatutride ( n = 98, NCT04881760) 168 , have shown promising results in resolving MASH and reducing body weight, and are…”
Self-citationSuresh, M. G., Mohamed, S., Geetha, H. S., Prabhu, S., Trivedi, N., Ng, Z. C., Mehta, P. D., Brar, A. S., Sohal, A., Goyal, M. K., et al. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i2.113149 · Cited by 35
The real‐life experiences of people living with overweight and obesity: A psychosocial perspective
Flint, S. W., Vázquez‐Velázquez, V., Brocq, S. L., & Brown, A. C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16255 · Cited by 35
“21 What is clear is the need for multidisciplinary support for people living with obesity who are accessing weight management and obesity services, and as noted throughout this article, consideration of the psychosocial aspects of obesity in the design, delivery and evaluation of interventions.”
Rinella, M. E., & Sookoian, S. C. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01187-8 · Cited by 34
“Incretin-based therapies have demonstrated impressive effects on weight loss, glycaemic control and MASH resolution 11,13–15 .”
Steatotic liver disease and cancer: from pathogenesis to therapeutic targets
Yang, Z., Liu, Z., Liu, W., & Dong, X. C. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100218 · Cited by 33
Modeling the health and economic impact of pharmacologic therapies for MASLD in the United States
Wallace, C., Gamkrelidze, I., Estes, C., Razavi, H., & Sanyal, A. J. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.009 · Cited by 27
Self-citationMisra, A., Kumar, A., Kuchay, M. S., Ghosh, A., Gulati, S., Choudhary, N. S., Dutta, D., Sharma, P., Vikram, N. K., Rastogi, A., et al. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103209 · Cited by 28
A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis
Lazarus, J. V., Brennan, P., Mark, H. E., Alazawi, W., Allen, A. M., Byrne, C. D., Castéra, L., Caussy, C., Cusi, K. J., Grajower, M. M., et al. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101320 · Cited by 34
Self-citationGoto, H., & Takamura, T. (2025) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes25017 · Cited by 30
“66,67 The direct effects of GLP-1 receptor agonists (GLP-1RA) on MASH pathology, independent of their effects on body weight, insulin resistance, and glycemic control, remain a topic of active investigation.”
Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention
Ostrominski, J. W., CHENG, A. Y. Y., Nelson, A. J., Neuen, B. L., Sattar, N. A., Tuttle, K. R., & Vaduganathan, M. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01384-4 · Cited by 35
Present and Future Perspectives in the Treatment of Liver Fibrosis
Cerrito, L., Galasso, L., Iaccarino, J., Pizzi, A., Termite, F., Esposto, G., Borriello, R., Ainora, M. E., Gasbarrini, A., & Zocco, M. A. (2025) · Pharmaceuticals · doi:10.3390/ph18091321 · Cited by 35
“The fibrosis reduction of at least one stage was achieved in 34% patients of the survodutide 2.4 mg group, 36% with 4.8 mg, 34% with 6.0 mg, and 22% with placebo [171].”
InfluentialSamson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 34
Mao, X., Zhang, X., Lai, R., Cheung, K. S., Yuen, M., Cheung, R. C., Seto, W., & Nguyen, M. H. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.1096 · Cited by 36
“10, 11 Although several observational studies show the benefits of GLP-1RA use to severe liver events in the general T2D population, 12, 13 this effect remains unclear in individuals with T2D and MASLD, and detailed information on primary liver-related disease burden (i.e. HCC or cirrhosis) in…”
Bile acid signaling in MASLD: From pathogenesis to therapeutic applications
Simbrunner, B., Paternostro, R., Reiberger, T., & Trauner, M. (2025) · Hepatology · doi:10.1097/hep.0000000000001539 · Cited by 32
Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
Zhou, D., & Fan, J. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003355 · Cited by 30
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
MacIsaac, R. J. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2511412 · Cited by 30
“Clinical studies involving GLP-1 RAs therapy coupled with glucagon receptor (GCGR) agonists (survodutide) or amylin analogues (cagrilintide) are also demonstrating favorable metabolic-related outcomes [169–171].”
Gallo, G., Nalli, G., Baratta, F., Desideri, G., & Savoia, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168081 · Cited by 27
“After 52 weeks, tirzepatide was more effective than placebo in achieving MASH resolution without worsening fibrosis [249].”
Survodutide Once Weekly for the Treatment of Adults with Obesity
le Roux, C. W., Wharton, S., Startseva, E., Kloer, I. M., Hussain, S. A., Unseld, A., Bozkurt, B., Ard, J. D., Bays, H. E., Bogdański, P., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2600751 · Cited by 33
Self-citationDash, S. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15829 · Cited by 24
Metadata
- Authors
- Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., Hosseini-Tabatabaei, A., Schattenberg, J. M., Noureddin, M., Alkhouri, N., & Younes, R.
- Affiliations
- Inserm (FR)
- From the Stravitz–Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond (A.J.S.); Liverpat and University of Paris (P.B.), and Sorbonne Université, Institute for Cardiometabolism and Nutrition, Assistance Publique–Hôpitaux de Paris, INSERM Unité Mixte de Recherche Scientifique 1138, Centre de Recherche des Cordeliers (V.R.) — all in Paris; Boehringer Ingelheim, Ingelheim am Rhein (M.F., S.A.H and R.Y.), Saarland University Medical Center, Homburg (J.M.S.), and University of the Saarland, Saarbrücken (J.M.S.) — all in Germany; Covenant Metabolic Specialists, Sarasota, FL (G.W.N.); Houston Methodist Hospital and Houston Research Institute, Houston (M.N.), and the Texas Liver Institute, University of Texas Health San Antonio, San Antonio (E.L. and N.A.) — all in Texas; the University of Turin, Turin, Italy (E.B.); the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, and Newcastle National Institut...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-25
- Volume
- 391
- Issue
- 4
- Pages
- 311-319
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399439504
- Cited by
- 528
- References
- 28
- Citations by year
- 2026: 212 · 2025: 237 · 2024: 79
- FWCI
- 159.28
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by-nc-nd)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- survodutide, nonalcoholic steatohepatitis, liver fibrosis, glucagon receptor agonist, GLP-1 receptor agonists, liver fat, histologic improvement, dose-response relationship, adverse events, non-alcoholic fatty liver disease, drug safety and efficacy, dose escalation, maintenance phase
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Fatty Liver, Female, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged, Receptors, Glucagon
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.